Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lisata Therapeutics ( (LSTA) ) just unveiled an announcement.
On January 23, 2026, Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. mutually agreed to terminate their exclusive license and collaboration agreement, originally signed in February 2021 and subsequently amended, which had granted Qilu rights to research, develop and commercialize certepetide in Greater China. The termination, effective the same day, eliminates Lisata’s potential to receive up to $200 million in development and commercial milestone payments and 10%–15% royalties on sales in that territory, although both parties remain bound by obligations and certain provisions that accrued or were designated to survive prior to the termination, signaling a strategic shift in Lisata’s regional commercialization plans for certepetide.
The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large operating losses, and ongoing cash burn). Offsetting this, the latest earnings call showed meaningful cost discipline and cash runway into early 2027, and the announced acquisition term sheet provides a strong near-term positive catalyst. Technicals are moderately supportive, while valuation metrics provide limited help due to negative earnings and no dividend yield provided.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of innovative therapeutics, including certepetide (formerly known as CEND-1), with prior efforts to expand its presence in the Greater China market through out-licensing arrangements.
Average Trading Volume: 160,707
Technical Sentiment Signal: Hold
Current Market Cap: $35.9M
For detailed information about LSTA stock, go to TipRanks’ Stock Analysis page.